NPI: 1003229766 · KISSIMMEE, FL 34743 · End-Stage Renal Disease (ESRD) Treatment Clinic/Center · NPI assigned 06/10/2014
Authorized official WEY, SAMUEL controls 20+ related entities in our dataset. Read more
| Authorized Official | WEY, SAMUEL (VP, LICENSURE & CERTIFICATION) |
| NPI Enumeration Date | 06/10/2014 |
Other providers sharing the same authorized official: WEY, SAMUEL
| Provider | City | State | Total Paid |
|---|---|---|---|
| DVA HEALTHCARE RENAL CARE INC | NORTH HOLLYWOOD | CA | $16.47M |
| DVA HEALTHCARE RENAL CARE INC | DELANO | CA | $16.43M |
| DVA RENAL HEALTHCARE INC | LOS ANGELES | CA | $15.51M |
| DVA RENAL HEALTHCARE INC | SAN DIEGO | CA | $14.93M |
| DVA RENAL HEALTHCARE INC | SAN DIEGO | CA | $13.67M |
| DVA RENAL HEALTHCARE INC | OAKLAND | CA | $13.42M |
| DVA RENAL HEALTHCARE INC | SAN DIEGO | CA | $13.25M |
| DVA HEALTHCARE RENAL CARE INC | YUMA | AZ | $12.88M |
| DVA HEALTHCARE RENAL CARE INC | BAKERSFIELD | CA | $12.77M |
| DVA RENAL HEALTHCARE INC | FULLERTON | CA | $12.19M |
| DVA HEALTHCARE RENAL CARE INC | POMONA | CA | $11.96M |
| DVA RENAL HEALTHCARE INC | ANAHEIM | CA | $11.32M |
| DVA RENAL HEALTHCARE INC | ESCONDIDO | CA | $10.94M |
| DVA HEALTHCARE RENAL CARE INC | COSTA MESA | CA | $10.08M |
| DVA HEALTHCARE RENAL CARE INC | INGLEWOOD | CA | $9.46M |
| DVA RENAL HEALTHCARE INC | VISALIA | CA | $9.22M |
| DVA RENAL HEALTHCARE INC | SAN DIEGO | CA | $8.83M |
| DVA HEALTHCARE RENAL CARE INC | BAKERSFIELD | CA | $8.56M |
| DVA HEALTHCARE RENAL CARE INC | INGLEWOOD | CA | $7.78M |
| DVA RENAL HEALTHCARE INC | PALM SPRINGS | CA | $7.48M |
| Year | Claims | Total Paid |
|---|---|---|
| 2018 | 16,921 | $2.53M |
| 2019 | 20,022 | $3.25M |
| 2020 | 19,491 | $2.96M |
| 2021 | 11,704 | $1.17M |
| 2022 | 5,288 | $566K |
| 2023 | 1,733 | $91K |
| 2024 | 648 | $32K |
| Code | Description | Claims | Beneficiaries | Total Paid |
|---|---|---|---|---|
| Q4081 | Injection, epoetin alfa, 100 units (for esrd on dialysis) | 26,331 | 1,218 | $3.36M |
| 90999 | Unlisted dialysis procedure, inpatient or outpatient | 21,658 | 1,591 | $3.12M |
| J1270 | Injection, doxercalciferol, 1 mcg | 14,329 | 1,004 | $2.09M |
| A4657 | Syringe, with or without needle, each | 2,827 | 1,135 | $575K |
| J1756 | Injection, iron sucrose, 1 mg | 4,728 | 830 | $563K |
| 85041 | 1,172 | 758 | $185K | |
| 85048 | 1,174 | 759 | $185K | |
| G0499 | Hepatitis b screening in non-pregnant, high risk individual includes hepatitis b surface antigen (hbsag), antibodies to hbsag (anti-hbs) and antibodies to hepatitis b core antigen (anti-hbc), and is followed by a neutralizing confirmatory test, when performed, only for an initially reactive hbsag result | 720 | 278 | $102K |
| 83970 | 745 | 451 | $100K | |
| 83540 | 645 | 402 | $88K | |
| 83550 | 641 | 402 | $88K | |
| 82728 | 587 | 380 | $81K | |
| J0604 | Cinacalcet, oral, 1 mg, (for esrd on dialysis) | 93 | 52 | $38K |
| 82108 | 79 | 55 | $16K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | 78 | 54 | $16K |